Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of PF-07275315 and PF-07264660 in adults with moderate to severe atopic dermatitis
2023-505218-68-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-07275315, PF-07264660 and Placebo (3 arms). Primary endpoint: EASI75 at Week 16. Planned start Jun 2025; status: authorised.
02
Drugs
tilrekimigompekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-505218-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505218-68-00.